Search Within

Suzanne M Chanel

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Adult Leukemia (8)
  2. Center for Hematologic Malignancies (8)
  3. Department of Medicine (8)
  4. Hematologic Malignancies, Division of (8)
  5. Molecular Imaging and Therapy Service (8)
  6. Nursing (8)

More Groups

People
  1. David Scheinberg (6)
  2. Michael Mcdevitt (6)
  3. Neeta Pandit-Taskar (6)
  4. Steven Larson (6)
  5. Joseph Jurcic (5)
  6. Todd Rosenblat (5)

More People

Years
  1. 2013 (1)
  2. 2011 (2)
  3. 2010 (2)
  4. 2008 (1)
  5. 2007 (1)
  6. 2006 (1)
Publications
  1. Blood (4)
  2. Cancer Biotherapy and Radiopharmaceuticals (1)
  3. Clinical Cancer Research (1)
  4. Journal of Clinical Oncology (1)
  5. Leukemia Research (1)
Publishers
  1. American Society of Hematology (4)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Ltd (1)
  5. Mary Ann Liebert, Inc (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors
    Journal Article

    Berman, E.; Girotra, M.; Cheng, C.; Chanel, S.; Maki, R.; Shelat, M.; Strauss, H. W.; Fleisher, M.; Heller, G.; Farooki, A.
    Leukemia Research (2013)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Ryan, C.; Frattini, M. G.; Cicic, D.; Larson, S. M.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 (ac-225)-lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML)
    Meeting Abstract

    Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Zikaras, K.; Frattini, M. G.; Maslak, P. G.; Cicic, D.; more...
    Blood (2011)

    Fulltext@MSK | Save
  • Effects of long term imatinib on bone mineral density in patients with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Berman, E.; Maki, R.; Farooki, A.; Girotra, M.; Chanel, S.; Cheng, C.; Strauss, H. W.; Fleisher, M.
    Blood (2010)

    Fulltext@MSK | Save
  • Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Journal Article

    Rosenblat, T. L.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Divgi, C. R.; Panageas, K. S.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Sgouros, G.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Sequential cytarabine and alpha-particle immunotherapy with bismuth-213 ((213)Bi)-labeled-HuM195 (lintuzumab) for acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Weiss, M. A.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 (Ac-225)-HuM195 (Anti-CD33) in acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S.; Frattini, M. G.; Larson, S. M.; Scheinberg, D. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225
    Meeting Abstract

    Jurcic, J. G.; McDevitt, M. R.; Pandit-Taskar, N.; Divgi, C. R.; Finn, R. D.; Sgouros, G.; Apostalidis, C.; Chanel, S.; Larson, S. M.; Scheinberg, D. A.
    Cancer Biotherapy and Radiopharmaceuticals (2006)

    Fulltext@MSK | Save